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Abstract
Acute Kidney Injury (AKI), an abrupt deterioration in kidney function, is defined
by changes in urine output or serum creatinine. AKI is common (affecting up to
20% of acute hospital admissions in the United Kingdom), associated with
significant morbidity and mortality, and expensive (excess costs to the National
Health Service in England alone may exceed £1 billion per year). NHS England
has mandated the implementation of an automated algorithm to detect AKI
based on changes in serum creatinine, and to alert clinicians. It is uncertain,
however, whether ‘alerting’ alone improves care quality.
 
We have thus developed a digitally-enabled care pathway as a clinical service
to inpatients in the Royal Free Hospital (RFH), a large London hospital. This
pathway incorporates a mobile software application - the “Streams-AKI” app,
developed by DeepMind Health - that applies the NHS AKI algorithm to
routinely collected serum creatinine data in hospital inpatients. Streams-AKI
alerts clinicians to potential AKI cases, furnishing them with a trend view of
kidney function alongside other relevant data, in real-time, on a mobile device.
A clinical response team comprising nephrologists and critical care nurses
responds to these AKI alerts by reviewing individual patients and administering
interventions according to existing clinical practice guidelines.
 
We propose a mixed methods service evaluation of the implementation of this
care pathway. This evaluation will assess how the care pathway meets the
health and care needs of service users (RFH inpatients), in terms of clinical
outcome, processes of care, and NHS costs. It will also seek to assess
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  (0)Commentsoutcome, processes of care, and NHS costs. It will also seek to assess
acceptance of the pathway by members of the response team and wider
hospital community. All analyses will be undertaken by the service evaluation
team from UCL (Department of Applied Health Research) and St George’s,
University of London (Population Health Research Institute).
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Introduction
Acute kidney injury (AKI) is a sudden loss of kidney function, 
defined by a rise in serum creatinine or a fall in urine volume1. It 
has diverse causes, which include sepsis or acute infection, hypo-
volaemia or hypoperfusion, nephrotoxicity (from drugs or radio-
logical contrast), obstruction of the renal tract, and primary renal 
diseases such as acute glomerulonephritis. In the United Kingdom, 
AKI affects up to 15% of hospital admissions and 20% of emer-
gency admissions2,3. AKI may result in fluid overload, respiratory 
failure and metabolic derangements such as hyperkalaemia4, and is 
thus strongly associated with adverse outcomes including death5, 
prolonged hospitalisation6, requirement for renal replacement 
therapy7, and a need for high dependency or intensive care8. It is 
also associated with an increased lifetime risk of chronic kidney 
disease9. AKI is also expensive: the associated excess costs to the 
National Health Service (NHS) in England may exceed £1 billion 
per annum3.
Management of AKI involves four processes of care: timely 
recognition, general supportive care, therapy directed at the 
underlying cause, and management of complications. Across 
the NHS, there are substantial cross-pathway deficits in care10. 
Increasing awareness of these and of the clinical and economic 
impact of this condition has led to local, regional, national and 
global initiatives to try to prevent AKI from occurring, and 
to encourage timely and appropriate interventions to prevent 
progression and deliver more rapid recovery. Clinical practice 
guidelines for the management of AKI have now been developed11.
More recently, on the basis that the prompt and reliable identifica-
tion of AKI cases to clinicians may trigger improved care, NHS 
England issued a national patient safety alert on “standardising 
the early identification of Acute Kidney Injury”12. This mandated 
the installation of a new detection algorithm in each NHS hos-
pital, so that potential AKI incidents could be flagged to treating 
clinicians. The ‘Think Kidneys’ NHS England National pro-
gramme has provided best practice examples of how AKI alerts 
may be clinically deployed13. However, simply alerting a clinician 
to the presence of a possible AKI incident may be insufficient to 
improve outcomes14. A much richer clinical dataset is required 
to help clinicians prioritise, diagnose and manage patients. The 
UK’s National Institute for Health and Care Excellence (NICE) 
guidelines on AKI management suggest that patients with more 
severe AKI might benefit from care delivery by suitably expert 
clinicians, for example as part of a ‘rapid referral’ nephrology 
service11.
The Royal Free Hospital (RFH) will implement existing standards 
for best practice through deployment of a digitally-enabled care 
pathway as a core service to hospital inpatients. A key compo-
nent of this is a mobile software application (Streams-AKI). This 
application will identify potential new cases of AKI by applying 
the NHS AKI algorithm to a live stream of serum creatinine data, 
providing real-time monitoring of kidney function. The application 
will provide real-time alerts of potential AKI cases, alongside other 
critical clinical data, to a clinical response team comprising neph-
rologists and critical care nurses. This response team will assess the 
data provided by the application, prioritise cases and then deliver 
investigations and therapies according to current best practice 
guidelines11. 
We propose a service evaluation of the introduction of the digit-
ally-enabled care pathway with respect to processes of care, patient 
outcomes, qualitative feedback from patients and staff, and NHS 
costs.
Aims and objectives
This service evaluation aims to assess the benefits of the imple-
mentation of the digitally-enabled AKI pathway from January 
2017, with respect to clinical outcome, renal recovery, processes of 
care, and NHS costs. The evaluation will also assess the experi-
ence of service users (RFH in-patients who have been treated by 
the pathway), members of the clinical response team and the wider 
clinical community of RFH.
Methods
Service evaluation setting
The Streams-AKI app and clinical response team are deployed at a 
single hospital site within the Royal Free London Foundation Trust 
(RFLFT): the RFH, an 800-bed teaching hospital which also pro-
vides diverse specialist and tertiary services, including a dialysis 
unit and 34-bed intensive care unit with renal replacement therapy 
onsite. The outcomes of this evaluation will inform further devel-
opment of the care pathway and its deployment in other RFLFT 
sites.
Following the implementation of the digitally-enabled care 
pathway, data from the RFH will be compared with data from the 
RFH prior to deployment in addition to pre-deployment and post- 
deployment data from a second hospital that is part of the 
RFLFT, Barnet General Hospital (BGH). BGH is a 450-bed 
district general hospital providing acute care (including onsite 
renal replacement therapy, a 21-bed ITU and on-site nephrology 
services), with similar arrangements for the care of AKI patients 
to that at the RFH prior to implementation of the digitally-enabled 
care pathway.
The RFH has onsite wireless internet networks available to 
clinicians, and was classified as a global digital exemplar (GDE) 
by NHS England in April 2016.
The AKI care pathway prior to implementation. Serum creati-
nine, an indicator of kidney function, is currently measured in the 
hospital laboratory. The current AKI detection algorithm in the 
laboratory information management system (which predates the 
      Amendments from Version 1
The article has been revised in response to two referee reports. 
We have clarified the timeline for clinical intervention, and the 
rationale behind using Barnet General Hospital as a comparator 
site. A section has been added to discuss the determination 
by the Office of the Information Commissioner. Finally, we have 
added a follow-up measurement of renal function to the list of 
secondary outcomes, and have appended the care protocol as a 
Supplementary Figure.
See referee reports
REVISED
Page 3 of 15
F1000Research 2017, 6:1033 Last updated: 10 AUG 2017
national algorithm) identifies potential AKI cases and presents 
a message for clinicians in both the hospital results system and 
electronic patient record. This message also flags the availability 
of clinical guidance and education via a link to a webpage display-
ing local guidelines (www.londonaki.net). Prior to implementation, 
such results were normally batch reviewed by nonspecialists at 
the end of the day and may have been seen several hours after the 
results first become available. Clinicians may have opted to review 
results earlier, but this process relied upon repeated accessing of 
the results systems, as clinicians did not know when results were 
ready. Where blood tests suggested AKI, this may have been com-
municated by telephone to the clinical teams responsible for the 
patient by the biochemistry laboratory. However, this process was 
cumbersome and may have been unreliable.
Patients develop AKI in multiple wards and settings. Early man-
agement of AKI was overwhelmingly delivered by nonspecial-
ist, ward-based teams with primary clinical responsibility for the 
patient. Specialist nephrology review of kidney function blood tests 
or of patients with AKI only occurred if requested by the patient’s 
responsible (or ‘home’) clinical team. This required the home team 
to assess kidney function results, assess the patient, decide to option 
a specialist review, contact the renal team via phone or pager sys-
tems and await a response. The renal team would then receive ver-
bal referral information or would manually access results and other 
clinical data to prioritise the referral, managing information relating 
to multiple referrals with paper-based processes. The hospital’s crit-
ical care nursing team did not receive automated referrals and were 
entirely reliant on being contacted by pager systems when ward 
staff were concerned that a patient was deteriorating.
The RFLFT deployed clinical guidelines and had an active AKI 
education programme to support clinical teams, but local audit 
showed that performance in managing AKI varied, and did not 
always consistently meet national standards15. Quality improve-
ment in AKI care is a RFLFT organisational priority, and has driven 
the development of the care pathway and its proposed evaluation.
The digitally-enabled care pathway comprising the 
Streams-AKI app and the AKI clinical response team
The digitally-enabled care pathway is the service whose implemen-
tation is being evaluated.
The Streams-AKI application. Streams-AKI is a mobile applica-
tion that is deployed on iPhone Operating System (iOS)-enabled 
smartphones. It processes routinely-collected demographic data 
(i.e. patient identifiers, location, responsible consultant, and respon-
sible medical specialty), and also serum creatinine data in real time 
according to the nationally mandated NHS AKI algorithm, which 
grades patients’ AKI stage from 1 to 3. When the algorithm identi-
fies a case of AKI, a patient-specific notification is delivered directly 
to the clinician user’s iOS device. In current clinical practice, clini-
cians must distinguish patients with clinically relevant changes in 
creatinine from those without, through review of current and his-
torical blood tests, or elements of past medical history that indicate 
disease causality, complications or pre-existing risk. These routine 
data are therefore displayed in-app alongside the AKI alert to facili-
tate interpretation and clinical decision making. The Streams-AKI 
app is fully integrated with the existing RFH electronic health record 
system, and operates on Fast Healthcare Interoperability Resources 
(FHIR) interoperability standards. During implementation, it will 
be utilised alongside existing electronic health record software. 
Data security is ensured through the use of on-disk (AES256) and 
in-flight encryption (TLS v1.2) for all app data in compliance with 
NHS Digital information security guidelines. The app was first 
registered with the Medicines and Healthcare Products Regulatory 
Agency (MRHA) as a Class I, non-measuring, non-sterile medical 
device on 30/08/2016.
The clinical response team. At the RFLFT, Streams-AKI will be 
installed on RFLFT-owned iOS devices. These will be held by 
members of a dedicated clinical response team, consisting of a clin-
ical lead nephrologist, a duty consultant nephrologist, a specialty 
nephrology registrar, and a critical care outreach nurse. Following 
in-app review of alerts, all patients determined to be suffering from 
clinically-relevant AKI will receive a prompt bedside review form 
the nephrology team. The timeline to intervention after alerts has 
not been standardized, recognising that ‘real world’ clinical pres-
sures and judgement may require prioritisation of actions within 
available resource constraints. We have, instead, specified immedi-
ate review for patients with life threatening results (e.g. hyperkalae-
mia), and that other, less urgent, cases are viewed within hours. The 
Streams app allows clinicians to view results and triage patients for 
early review based on perceived clinical urgency. The timeframe 
for review will therefore depend on clinical prioritisation and other 
(clinically determined) variable demands.
Members of the clinical response team will then administer a stand-
ardized care protocol. The critical care outreach nurse will also 
receive alerts on more severe (stage 2 and 3) cases and will respond 
to the most severely unwell cases according to clinical judgement 
of patient risk. All interventions and future care requirements will 
be communicated to responsible clinicians verbally and through a 
standard written proforma (Supplementary Figure 1) entered into 
the patient record. Where necessary, the clinical response team will 
arrange a further review within 24 hours. The Streams-AKI app will 
further alert the team if the patient’s AKI stage subsequently wors-
ens and will also alert after 48 hours if a patient is still suffering 
from AKI, as determined by the national AKI algorithm. The team 
will respond to such follow up alerts according to best practice and 
clinical judgement.
All clinicians using the app first receive training. This comprises:
-    A detailed review of the Streams-AKI app
-    Introduction to the devices being used to host the app: RFLFT-
owned iPhones (Apple, Inc., Cupertino, Calif., USA)
-    An introduction to the other members of the response team
-    Review of the standardised digitally-enabled AKI care protocol.
Streams-AKI was deployed in January 2017. Following a pilot 
phase of 12 weeks to allow optimisation of the care pathway, an 
18-week evaluation phase commenced, during which outcome data 
will be accrued (see Figure 1). For comparative analysis, data will 
be collected from the two hospital sites (RFH and BGH) at three 
time points:
-    One year before deployment (January to August 2016)
-    Immediately before deployment (September 2016 to January 
2017)
-    During deployment (January to August 2017)
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Table 1. Definitions and data sources for all process of care outcome measures.
Outcome measure Definition Source of data
Recognition of AKI Time of documentation of recognition of AKI  
(digitally in-application or through written notes)
Electronic/Paper note review, data 
aggregated within the Streams 
data processor
Recognition of 
possible underlying 
cause
Time of documentation of possible cause(s) of AKI as: 
      -      Sepsis 
      -      Hypovolaemia 
      -      Obstruction 
      -      Nephrotoxins 
      -      Parenchymal disease
Electronic/Paper note review
Time to investigation Time of documentation of: 
      -      Diagnostic imaging for obstruction 
      -      Diagnostic blood test or renal biopsy for 
             parenchymal kidney disease
Electronic/Paper note review
Time to treatment Time of documentation of: 
      -      Delivery of antibiotics for sepsis 
      -      Delivery of fluid for hypovolaemia 
      -      Relief of obstruction 
      -      Withdrawal of nephrotoxins 
      -      Definitive treatment for parenchymal kidney 
             disease
Electronic/Paper note review
Time to specialist 
referral
Time of documented referral to: 
      -      Nephrology 
      -      Urology 
      -      High Dependency or Intensive Care Unit
Electronic/Paper note review
Time to specialist 
review
Time of documented review by: 
      -      Nephrology team 
      -      Urology team 
      -      High Dependency or Intensive Care Unit
Electronic/Paper note review
An interim analysis is planned half way through the evaluation 
phase. Results from this may inform the duration of the service 
evaluation.
Evaluation sample. The service implementation evaluation will 
include data from all inpatients triggering an AKI alert as defined 
by the national AKI detection algorithm who are aged 18 or over.
Utilising a daily data feed from the RFLFT chronic dialysis data-
base, AKI alerts for patients receiving kidney dialysis will be iden-
tified by the application itself and removed. Alerts for inpatients 
on the Acute Kidney or Critical Care Units will also be removed. 
Figure 1. Evaluation phases. Phases of the evaluation are listed in order. A summary of the main aims of each phase is also listed. The 
digitally-enabled care pathway was implemented in January 2017.
?????????????????????????
???????????
???????????????????????? ??????????????????????????
?????????? ??????????
????????????????
-   App creation
-   Usability testing
-   Inception of the care protocol
-   Training of response team members
-  Observation of response team
-  Interviews with response team
-  Interviews with response team
-  Interviews with clinicians
? ? ????????????????????? ??????????????????????????????????????????????????????-   Integration with existing RFH infrastructure
?
* Implementation of digitally-enabled care pathway
Patients on an end-of-life pathway at the time of the AKI alert will 
be excluded.
Outcome measures. The evaluation of the pathway will employ a 
mixture of both quantitative and qualitative methods. The primary 
outcome will be recovery of renal function, which will be defined 
as a return to a creatinine level within 120% of the baseline (as 
defined by the National AKI algorithm) prior to discharge from 
hospital. Secondary outcomes will be categorised into four areas: 
processes of care, clinical outcomes, Trust-wide metrics, and NHS 
costs. Definitions of each outcome, and the sources of all data to be 
collected, are provided in Table 1–Table 4.
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Table 2. Definitions and data sources for all clinical outcome measures. Health Level 7 (HL7) messages 
are used to transfer information between different healthcare IT systems.
Outcome measure Definition Source of data
Presence of AKI 
complications
Presence of: 
      -      Hyperkalaemia 
      -      Acidosis 
      -      Uraemia 
      -      Peripheral oedema 
      -      Pulmonary oedema 
During index admission
Electronic/Paper note review, 
HL7 data* aggregated within the 
Streams-AKI data processor
Recovery of renal function Return to <120% index creatinine (as 
defined by NHS diagnostic algorithm)  
by the time of hospital discharge
HL7 data aggregated within the 
Streams-AKI data processor
Time to recovery of renal 
function
The time from AKI alert to recovery of 
renal function (<120% index creatinine).
HL7 data aggregated within the 
Streams-AKI data processor
Progression of AKI stage Movement between AKI severity classes 
following AKI alert and prior to hospital 
discharge
HL7 data aggregated within the 
Streams-AKI data processor
Mortality Death in 30 days following AKI alert HL7 data aggregated within the 
Streams-AKI data processor
Length of stay Time from AKI alert to hospital discharge HL7 data aggregated within the 
Streams-AKI data processor
Admission to high acuity or 
specialist renal inpatient bed
Admission to: 
      -      Acute Kidney Unit (AKU) or other 
             renal ward 
      -      High Dependency Unit (HDU) 
      -      Intensive Treatment Unit (ITU) 
During index admission
HL7 data aggregated within the 
Streams-AKI data processor
Length of stay in high acuity 
bed
Length of stay on: 
      -      AKU 
      -      HDU 
      -      ITU 
During index admission
HL7 data aggregated within the 
Streams-AKI data processor
Requirement for immediate 
temporary renal replacement 
therapy
Use of: 
      -      Haemofiltration 
      -      Haemodiafiltration 
      -      Haemodialysis 
      -      Peritoneal dialysis 
After AKI alert, but during index admission
HL7 data aggregated within the 
Streams-AKI data processor/
Trust submissions to the Health 
Episode Statistics- Admitted 
Patient Care database
Requirement long-term renal 
replacement therapy
Use of: 
      -      Haemofiltration 
      -      Haemodiafiltration 
      -      Haemodialysis 
      -      Peritoneal dialysis 
In 30 days following hospital discharge date
The Trust’s Nephrology Clinical 
Information Management 
System (VitalData) and Health 
Episode Statistics Admitted 
Patient Care database.
Readmission to hospital Readmission to hospital in 30 days 
following index admission discharge date
HL7 data aggregated within the 
Streams-AKI data processor
Follow-up renal function Last available creatinine obtained in 
outpatients or on discharge following 
another hospitalization between 90 and 
365 days after index hospital discharge
HL7 data aggregated within the 
Streams-AKI data processor
Qualitative evaluation. During the 12-week pilot phase, the clinical 
response team was observed by a member of the service evalua-
tion team, allowing key issues relating to both the technological and 
clinical aspects of the enhanced care pathway (including resource 
use) to be recorded. Semi-structured interviews were carried out 
with a selection of response team members (including nephrology 
consultants and specialty registrars, and critical care outreach 
nurses). The interviews explored whether the clinical response 
team members found that the new care pathway and the Streams-
AKI application helped them provide best-practice care for 
patients, which aspects of the digitally-enabled pathway worked 
well or where they could be improved, adverse experiences or 
Page 6 of 15
F1000Research 2017, 6:1033 Last updated: 10 AUG 2017
Table 3. Definitions and data sources for Trust-wide outcome metrics.
Metric Definition Source of data
Referrals to critical 
care nursing team
Number of patients referred for review by critical 
care outreach nurses per 1000 bed days
Trust critical care nursing team logs
Unplanned 
admissions to ITU
Number of unplanned admission episodes in 
intensive care per 1000 bed days 
Trust submissions to Intensive Care 
National Audit & Research Centre
Cardiac arrest rate Number of cardiac arrests per 1000 bed days Trust critical care nursing team logs
Table 4. Definitions and data sources for NHS cost outcome measures.
Cost Outcome Definition Source of data
Use of renal replacement 
therapy (resource use 
measured in days)
Use of: 
      -      Haemofiltration 
      -      Haemodiafiltration 
      -      Haemodialysis 
      -      Peritoneal dialysis
HL7 data aggregated within the Streams-AKI data 
processor/Trust submissions to the Health Episode 
Statistics- Admitted Patient Care database, and 
Payment by Results/local tariffs at the Trust
Length of stay on a 
regular inpatient ward
Length of stay outside: 
      -      AKU 
      -      HDU 
      -      ITU 
During index admission
HL7 data aggregated within the Streams-AKI data 
processor, and Payment by Results/local tariffs at 
the Trust
Length of stay in high 
acuity bed
Length of stay inside: 
      -      AKU 
      -      HDU 
      -      ITU 
During index admission
HL7 data aggregated within the Streams-AKI data 
processor, and Payment by Results/local tariffs at 
the Trust
Readmission to hospital Readmission to hospital in 30 days 
following index admission discharge date
HL7 data aggregated within the Streams-AKI data 
processor, and Payment by Results/local tariffs at 
the Trust
Staffing costs An estimate of staffing cost associated  
with the delivery of usual care vs. the 
Streams-AKI care pathway
Staff observation exercise
Cost of investigations An estimate of costs associated with 
interventions made and/or investigations 
ordered as a result of AKI
Staff observation exercise, HL7 data aggregated 
within the Streams-AKI data processor
consequences of app use, and any unexpected indirect beneficial 
or adverse effects. Observational work and interviews carried out 
during the pilot phase were used to drive iterative improvements 
in the digitally-enabled care pathway prior to the beginning of the 
evaluation phase.
At the conclusion of the evaluation phase, a selection of doctors and 
nurses will be invited to a second series of semi-structured inter-
views. We will specifically target those responsible for the care of 
those patients who have been reviewed by the AKI response team 
during the evaluation. Participants will be purposively sampled to 
include a mixture of grades of clinicians (House Officers; Senior 
House Officers; Registrars; Consultants) and nurses (Staff Nurse; 
Charge Nurse). These will explore strengths and weaknesses of the 
digitally-enabled care pathway; how these map to perceived defi-
ciencies in AKI care; how the new pathway affected the quality 
and equity of patient care; and how they feel the service could be 
improved. Approximately 20 interviews will be carried out. The 
exact number of health care professionals interviewed will be 
determined by the need to achieve sufficient diversity in elicited 
accounts for the questions to fully address all major themes, with 
no new issues arising at further interviews.
Figure 1 outlines the timeframes for each phase of the service 
evaluation, as described above.
Statistical analysis plan and power calculation
We will use interrupted time series segmented regression analysis 
to examine the effect of the new AKI service on the weekly patient 
recovery rate for acute kidney injury within 30 days; recovery is 
defined as a return to creatinine level within 120% of baseline 
level. The primary dependent variable (recovery of renal function) 
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will be modelled using a generalised linear model assuming a 
binomial distribution and using a logit link. This modelling 
approach will ensure that predicted values yielded from the model 
cannot fall outside the valid 0–100% range. We will also allow 
for autocorrelation in the model, which can be an issue with time 
series data. Using this approach, it will be possible to test 
for a change in level and/or regression slope following the imple-
mentation of the intervention.
Pathological and clinical endpoints will also be compared to 
those from a partner hospital (BGH) not deploying the digitally- 
enabled care pathway over the same time period, and from the pre-
implementation periods as specified above. BGH has been included 
as a comparison site to allow us to demonstrate that impacts 
attributed to the service being evaluated are not due to systemic 
changes in process locally or nationally (e.g. relating to the National 
awareness campaign, ‘Think Kidneys’). Baseline care pathways are 
similar at BGH and RFH.
It is anticipated that the care pathway will be subsequently deployed 
in BGH, with such deployment informed by the results of this serv-
ice evaluation. Although comparison with the BGH comparator site 
should negate any seasonal effects, this is based on the assumption 
that the effect of time is the same in both intervention and com-
parator sites. The inclusion of the second pre-intervention period 
(i.e. immediately preceding the intervention period) will allow us to 
assess whether this is a fair assumption.
For the economic analysis, unit costs for each of the components 
will be obtained from two sources. First, we will use tariffs from 
the NHS National Tariff Payment System. Second, we will use 
local tariffs at RFLFT sites. Costs will be calculated using both 
sets of unit costs. We will multiply resource use by unit costs for 
each patient/cost component and sum across patients to calculate 
total costs per patient. The output will be a patient-level dataset 
of total costs per patient before and after the introduction of the 
digitally-enabled care pathway. Any attributable cost savings 
will be balanced against the additional costs of the alerting 
system and care pathway. This will include estimates of the use of 
clinician time; an activity observation exercise will be carried 
out with response team members during the evaluation period. 
A sensitivity analysis will be completed to assess the cost of 
care delivered to patients with AKI alerts that were discarded at 
clinician triage.
At the point of writing this service evaluation protocol, there are 
no published sample size calculations available for determin-
ing the number of timepoints needed for a well powered service 
evaluation using an interrupted time series design. In line with best 
practice in service evaluation, we therefore utilised simulations 
implementing the SIMSAM command in Stata (v14) (StataCorp 
LLC, College Station, Texas, USA) to establish the sample size 
needed. We simulated data containing weekly referral rates 
for four years prior to intervention, where the intervention will 
occur at 208 weeks. The average baseline recovery rate was 
assumed to be 0.51 (SD 0.08) which was determined using one 
year of pre-intervention data from the Royal Free Hospital, the 
site where the intervention will be implemented. One hundred 
observations (patients) or more per timepoint are encour-
aged16, which is a viable assumption based on historical data. A 
normally distributed random variable with mean of zero and stand-
ard deviation of 0.08 was generated to simulate the variation in 
recovery rate. The pre-intervention regression slope and the change 
in the effect of the intervention over time following the interven-
tion were both assumed to have an odds ratio of one. The recovery 
rate was generated as a function of these effects, the average 
baseline referral rate and the random variable.
The number of timepoints (measured on a weekly basis) needed 
to detect an odds ratio of 1.15 for the intervention effect with 90% 
power assuming a significance level of 5%, determined by simula-
tion, was 11 in total. This number of post-intervention timepoints 
increased to 32 if the size of effect to be detected has an odds ratio 
of 1.1, i.e. a 10% increase in the odds of recovery. The number of 
timepoints needed to detect an odds ratio of 1.1 for the interven-
tion effect with 80% power assuming a significance level of 5%, 
determined by simulation, was 20 in total. In further analyses, the 
segmented regression model will be extended to include a second 
hospital site for comparison of the change in level or change in 
slope post intervention. This will be Barnet Hospital, which will not 
receive the intervention. 
All other quantitative data collected (see Table 1) will be analysed 
using Stata. Data will be screened for normality and homogeneity 
of variance prior to analysis.
A series of interim analyses will be performed midway through 
the evaluation phase. These will include inter- and intra-operator 
analyses of variance for transcription of process of care data from 
patient notes, and initial modelling of primary outcomes. These 
analyses will be carried out by staff from University College 
London and St George’s University of London.
Analysis of qualitative data. The semi-structured interviews 
will be digitally recorded and transcribed verbatim. We will analyse 
the data from a realist viewpoint17, but our model will be revised to 
fit emerging interpretations of the data. We will apply a framework 
approach18, whereby the initial transcripts will undergo scrutiny 
by one member of the service evaluation team (AC) in order to 
gain familiarity with the data and to identify key themes. These 
will be discussed and further scrutinised with another service 
evaluation team member (RR), and with emerging interpreta-
tions or questions will be shared and critically explored with the 
with the entire service evaluation team. Transcripts will be 
analysed in a systematic manner by applying the coding frame-
work and by rearranging the data according to the thematic content. 
Generalisations that represent the total set and that address 
each of the objectives will be developed. During analysis, we will 
maintain a constant vigilance for deviant cases that may question 
the emerging thematic and conceptual relations.
Steering committee. A steering committee for this service 
evaluation has been convened at RFLFT. This committee includes 
an independent chair with no relationship to the project, a patient 
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service evaluation has also been presented to the UK’s 
National Institute for Health Research (NIHR) North Thames 
Collaboration for Leadership in Applied Health Research and 
Care (CLAHRC) Patient and Public Involvement Panel. The 
service evaluation has the full support of the Royal Free Kidney 
Patients Association.
It is theoretically possible that implementation of the digitally- 
enabled care pathway could have unforeseen adverse conse-
quences. These will be sought through clinical feedback at 
weekly Trust implementation meetings and monthly patient safety 
programme operational group meetings. Additionally, during 
the service evaluation, broad metrics of care quality and safety 
will be monitored by the Trust, and these will be reviewed by 
the independent steering committee at RFLFT for this evaluation 
(described above).
Dissemination of findings
Results will be presented to the renal, acute medicine and criti-
cal care departments, and to the RFLFT Patient Safety Committee 
and RFLFT Board. The findings will inform subsequent develop-
ments of the care pathway and will inform the RFLFT strategy for 
detecting and managing AKI. Data will also be presented on the 
Trust website via our patient safety portal and presented in lay 
language. Our findings will be shared at a learning event of the 
UCL Partners AKI Quality Improvement Collaborative, which has 
9 participant Trusts as well as a London AKI Network event and 
as a case study to Think Kidneys (the NHS England National AKI 
Programme). We will publish in relevant scientific journals, and 
present at conferences.
Competing interests
CL, HM, GR, and RR are paid clinical advisors to DeepMind. 
AC’s clinical research fellowship is part-funded by DeepMind. 
DeepMind will remain independent from the collection and 
analysis of all data. HM co-holds a patent on a fluid delivery device 
which might ultimately help in preventing some (dehydration-
related) cases of AKI occurring.
Grant information
The service evaluation will be conducted by NIHR-CLAHRC 
North Thames, based at UCL and directed by RR. RR is also 
an NIHR Senior Investigator. GR is funded in part by the NIHR 
University College London Hospitals Biomedical Research 
Centre. HM was similarly funded during project inception. The 
views expressed are those of the author(s) and not necessarily those 
of the NHS, the NIHR or the Department of Health.
member and a nephrologist from a different NHS Trust. This  
committee will review the results of the interim analyses discussed 
above.
Ethics, information and clinical governance
RFLFT uses Streams as part of its provision of care for patients. 
To support this service, DeepMind Health processes Patient Iden-
tifiable Data. This is in line with the governance arrangements 
for all other clinical software applications, and this arrangement 
forms part of an information processing agreement with the Trust, 
which has been published on the DeepMind website. The digitally- 
enabled care pathway will be a new standard service at RFH, and 
under NHS guidance there are therefore no consent requirements 
for patients for the processing of their personally identifiable data 
for direct patient care functions.
A determination by the Office of the Information Commissioner 
(ICO) was published in July 2017. This primarily focused on the 
clinical safety testing phase of Streams-AKI that occurred between 
app development (using only synthetic data) and the full clinical 
implementation that is being evaluated. The ICO ruled that the 
processing of data for the clinical safety testing of the application 
did not amount to processing for direct care purposes and so did not 
fully comply with data protection law. Concerns were also raised 
that not enough was done to ensure that patients and the public 
were aware of the project prior to data processing. RFLFT under-
took such clinical safety testing in the interests of patient safety, but 
has accepted the determination by the ICO and is in the process of 
completing her specified undertakings. The Trust statement on this 
determination is available on their website.
When undertaking the service evaluation, data will be transferred 
from RFLFT to the Department of Applied Research, University 
College London for analysis. Prior to transfer and analysis, all data 
will be de-identified, meaning that no consent will be required from 
patients for this purpose.
Plans for the evaluation of the digitally-enabled care pathway 
have been independently reviewed by the University College  
London Joint Research Office. They directed that this project falls 
under the remit of service evaluation, as per “Defining Research” 
guidance from the NHS Health Research Authority. As such, the 
service evaluation has been registered locally with the RFLFT 
Audit Lead and Medical Director. The service evaluation has 
the approval of the RFLFT Executive, RFLFT Board and Sub- 
Board Patient Safety Committee (including patient governor  
representatives and a non-Executive Chair and RFLFT Board 
Member). The Patient Safety Committee and RFLFT Board 
will receive reports on the results of the service evaluation. The  
Supplementary Data
Supplementary Figure 1: the standardized Streams-AKI proforma. The outcomes of patient review (including suggested interventions 
and future care requirements) are communicated to responsible clinicians via a standard written proforma that is entered into the patient 
record.
Click here to access the data.
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This is the publication of a protocol describing a much needed intervention study regarding the detection
and treatment of AKI. This project is clearly described and is already very advanced and close to the
completion stage.
 
This project relies on a new technology to rapidly process patient data through the NHS England national
algorithm for the detection of AKI. This technology then distributes AKI alerts, via an ‘app’ to a dedicated
specialist multi disciplinary clinical team who will then act according to national guidelines. The aim is to
improve outcomes of AKI.
 
This project tackles a complex medical problem yet I feel is appropriately designed to try and provide
answers to the following question; Does the provision of real time processing and delivery of patient data
regarding AKI to the dedicated MDT of clinicians, allow the implementation of an intervention (AKI care
bundles) that improves outcome.
 
The main difficulty will be demonstrating that outcome has improved, as this in itself is very hard to define
as a primary measure, and if it has not, where in the process has this failed. However, I think the
1,2
1
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1.  
as a primary measure, and if it has not, where in the process has this failed. However, I think the
methodology and the inclusion of a number of secondary outcome definitions is sensible, useful and
achievable in the context of the clinical problem. There is only really one other study that, unsuccessfully,
tried to answer similar clinical questions (Wilson  ) so the authors have minimal literature to guide themet al
yet there approach is sound. The analysis will incorporate a before and after side to the study at the
intervention hospital but there is also a second site control which again adds strength to the protocol.
 
This study cannot be replicated without access to the technology stream AKI app, however, should this
trial show benefit, a wider distribution by the sponsor to a number of different hospital types for a
multicentre study would seem logical.
 
I would however ask the authors to consider on further outcome measure metric. The literature is clear
that renal function measured by serum creatinine at discharge following significant illness can over
estimate renal function (Prowle  CJASN). This may confound the interpretation of success by a d/cet al 
creatinine being within 20% of baseline. A series of follow up creatinine measures at 3 and potentially 6
months would be a more robust measure of AKI treatment success as the long term effects of AKI on
renal function is potentially the most important success of early AKI intervention.
 
Finally, following recent media coverage in the UK in relation a court judgement regarding the sharing of
patient data between the RFLFT and DeepMind, can the authors clarify for the benefit of all readers that
this project remains legally and ethically sound.
 
I very much look forward to the results of this important study.
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Yes
 No competing interests were disclosed.Competing Interests:
Referee Expertise: AKI detection, management and follow up
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
Author Response 03 Aug 2017
, UCL, UKAlistair Connell
We thank Dr. Kirwan for his helpful comments, to which we are happy to be able to respond:
 
We agree that structured recording of follow-up creatinine at three and six months would be
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We agree that structured recording of follow-up creatinine at three and six months would be
highly desirable. RFLFT does not currently have the infrastructure to implement long term
hospital-based AKI follow-up for all patients with AKI exposed to the pathway under
evaluation, nor do we have funding or resource for such work at this time. This may be a
future development. However, we will present follow-up creatinine data from both
intervention and comparator sites and time periods where these are readily available
through existing clinical practice on the reviewer’s recommendation. Though
hospital-based, structured AKI follow up clinics are not part of the current service
improvement it is quite possible that more reliable detection and more rigorous early
management will result in more reliable AKI follow up either through referral to renal clinic,
non-renal secondary care clinics or through primary care follow up. We will attempt to study
this effect.
 
We fully understand the reviewer raising this point, and agree that it requires clarification.
The determination by the Office of the Information Commissioner (ICO) primarily focused on
the clinical safety testing phase of Streams-AKI that occurred between app development
(using only synthetic data) and the full clinical implementation that is being evaluated. The
ICO ruled that the processing of data for the clinical safety testing of the application did not
amount to processing for direct care purposes and so did not fully comply with data
protection law. Concerns were also raised that not enough was done to ensure that patients
and the public were aware of the project prior to data processing. RFLFT undertook such
clinical safety testing in the interests of patient safety, but has accepted the determination by
the ICO and is in the process of completing her specified undertakings. The Trust statement
on this determination is available on their website: 
https://www.royalfree.nhs.uk/patients-visitors/how-we-use-patient-information/information-commissioners-office-ico-investigation-into-our-work-with-deepmind/
 No competing interests were disclosed.Competing Interests:
 03 July 2017Referee Report
doi:10.5256/f1000research.12569.r23972
 Mitchell H Rosner
Division of Nephrology, University of Virginia, Charlottesville, VA, USA
The authors provide the rationale and study design for the implementation and evaluation of a
digitally-enable care pathway for the recognition and management of acute kidney injury (AKI). The paper
is well-written and the topic is timely given the impact of AKI on short and long-term outcome. This
program has the potential to radically change how patients with the earliest signs of AKI are managed and
the team should be applauded for these efforts. I had just a few minor queries:
It might be nice to show the actual protocol for intervention based upon the NICE guidelines
 
Is the timeline to intervention once the alert triggered standardized?
 
I am not sure I understand the rationale behind including Barnet General Hospital as compared to
RFH- it would seem that the patient mix (cardiac surgery, etc) might be very different between
these centers. Is there any methodology used to match causes of AKI and severity of illness?
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Overall, this is an exciting study with potentially profound implications for care of patients with AKI.
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Partly
Are the datasets clearly presented in a useable and accessible format?
Yes
 No competing interests were disclosed.Competing Interests:
Referee Expertise: Acute kidney injury
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
Author Response 03 Aug 2017
, UCL, UKAlistair Connell
We thank Prof. Rosner for his insightful comments, to which we are happy to be able to respond:
 
We have appended the care protocol for the intervention as a supplementary figure.
 
The timeline to intervention after alerts has not been standardized, recognising that ‘real
world’ clinical pressures and judgement may require prioritisation of actions within available
resource constraints. We have, instead, specified immediate review for patients with life
threatening results (e.g. hyperkalaemia), and that other, less urgent, cases are viewed
within hours. The Streams app allows clinicians to view results and triage patients for early
review based on perceived clinical urgency. The timeframe for review will therefore depend
on clinical prioritisation and other (clinically determined) variable demands.
 
Barnet General Hospital has been included as a comparison site to allow us to demonstrate
that impacts attributed to the service being evaluated are not due to systemic changes in
process locally or nationally (e.g. relating to the English national awareness campaign,
‘Think Kidneys’). Resources do not allow us to implement the new care pathway
simultaneously in Barnet and Hampstead sites, though we plan to implement the new
service on the Barnet site as part of our staged service improvement plans. Learning from
this evaluation will inform that process. We anticipate site-specific variation in outcomes
relating to casemix, as Professor Rosner rightly points out. Baseline care pathways are,
however, similar at Barnet and Hampstead sites: there is a legacy alert system in the results
viewing platform, non-specialists undertake batch review of results, biochemistry staff
phone out some AKI results, early care is administered by unsupervised non-specialist
teams with discretionary escalation to expert input via bleep or phone referrals. We thus feel
it is a useful site to compare process outcomes and time-series trends in both process and
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it is a useful site to compare process outcomes and time-series trends in both process and
outcome measures. We will collect demographic and clinical data for all patients with AKI at
both sites during the time periods stated, and will present descriptive comparison data at the
point of publication.
 No competing interests were disclosed.Competing Interests:
Page 15 of 15
F1000Research 2017, 6:1033 Last updated: 10 AUG 2017
